Literature DB >> 18483621

Bone marrow cells recruited through the neuropilin-1 receptor promote arterial formation at the sites of adult neoangiogenesis in mice.

Serena Zacchigna1, Lucia Pattarini, Lorena Zentilin, Silvia Moimas, Alessandro Carrer, Milena Sinigaglia, Nikola Arsic, Sabrina Tafuro, Gianfranco Sinagra, Mauro Giacca.   

Abstract

Experimental and clinical evidence indicate that bone marrow cells participate in the process of new blood vessel formation. However, the molecular mechanisms underlying their recruitment and their exact role are still elusive. Here, we show that bone marrow cells are recruited to the sites of neoangiogenesis through the neuropilin-1 (NP-1) receptor and that they are essential for the maturation of the activated endothelium and the formation of arteries in mice. By exploiting adeno-associated virus vector-mediated, long-term in vivo gene expression, we show that the 165-aa isoform of VEGF, which both activates the endothelium and recruits NP-1+ myeloid cells, is a powerful arteriogenic agent. In contrast, neither the shortest VEGF121 isoform, which does not bind NP-1 and thus does not recruit bone marrow cells, nor semaphorin 3A, which attracts cells but inhibits endothelial activation, are capable of sustaining arterial formation. Bone marrow myeloid cells are not arteriogenic per se nor are they directly incorporated in the newly formed vasculature, but they contribute to arterial formation through a paracrine effect ensuing in the activation and proliferation of tissue-resident smooth muscle cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18483621      PMCID: PMC2381745          DOI: 10.1172/JCI32832

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  53 in total

1.  Circulating endothelial precursors: mystery, reality, and promise.

Authors:  S Rafii
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

2.  Targeted delivery of bone marrow mononuclear cells by ultrasound destruction of microbubbles induces both angiogenesis and arteriogenesis response.

Authors:  Takanobu Imada; Tetsuya Tatsumi; Yasukiyo Mori; Takashi Nishiue; Masayuki Yoshida; Hiroya Masaki; Mitsuhiko Okigaki; Hiroyuki Kojima; Yoshihisa Nozawa; Yasunobu Nishiwaki; Noriko Nitta; Toshiji Iwasaka; Hiroaki Matsubara
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-07-28       Impact factor: 8.311

3.  Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease.

Authors:  T K Rosengart; L Y Lee; S R Patel; T A Sanborn; M Parikh; G W Bergman; R Hachamovitch; M Szulc; P D Kligfield; P M Okin; R T Hahn; R B Devereux; M R Post; N R Hackett; T Foster; T M Grasso; M L Lesser; O W Isom; R G Crystal
Journal:  Circulation       Date:  1999-08-03       Impact factor: 29.690

4.  Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve.

Authors:  S Rajagopalan; M Shah; A Luciano; R Crystal; E G Nabel
Journal:  Circulation       Date:  2001-08-14       Impact factor: 29.690

5.  Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor.

Authors:  S Soker; S Takashima; H Q Miao; G Neufeld; M Klagsbrun
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

6.  Arteriogenesis proceeds via ICAM-1/Mac-1- mediated mechanisms.

Authors:  Imo E Hoefer; Niels van Royen; John E Rectenwald; Elisabeth Deindl; Jing Hua; Marco Jost; Sebastian Grundmann; Michiel Voskuil; C Keith Ozaki; Jan J Piek; Ivo R Buschmann
Journal:  Circ Res       Date:  2004-04-01       Impact factor: 17.367

7.  Analysis of gene function in somatic mammalian cells using small interfering RNAs.

Authors:  Sayda M Elbashir; Jens Harborth; Klaus Weber; Thomas Tuschl
Journal:  Methods       Date:  2002-02       Impact factor: 3.608

8.  Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy.

Authors:  Emerson C Perin; Hans F R Dohmann; Radovan Borojevic; Suzana A Silva; Andre L S Sousa; Guilherme V Silva; Claudio T Mesquita; Luciano Belém; William K Vaughn; Fernando O D Rangel; Joao A R Assad; Antonio C Carvalho; Rodrigo V C Branco; Maria I D Rossi; Hans J F Dohmann; James T Willerson
Journal:  Circulation       Date:  2004-09-14       Impact factor: 29.690

9.  A requirement for neuropilin-1 in embryonic vessel formation.

Authors:  T Kawasaki; T Kitsukawa; Y Bekku; Y Matsuda; M Sanbo; T Yagi; H Fujisawa
Journal:  Development       Date:  1999-11       Impact factor: 6.868

10.  Adeno-associated virus-mediated transduction of VEGF165 improves cardiac tissue viability and functional recovery after permanent coronary occlusion in conscious dogs.

Authors:  Matteo Ferrarini; Nikola Arsic; Fabio A Recchia; Lorena Zentilin; Serena Zacchigna; Xiaobin Xu; Axel Linke; Mauro Giacca; Thomas H Hintze
Journal:  Circ Res       Date:  2006-03-16       Impact factor: 17.367

View more
  38 in total

Review 1.  CD34-positive stem cells: in the treatment of heart and vascular disease in human beings.

Authors:  Alexander R Mackie; Douglas W Losordo
Journal:  Tex Heart Inst J       Date:  2011

2.  Angiomyeloproliferative lesions following autologous stem cell therapy.

Authors:  Duangpen Thirabanjasak; Kavirach Tantiwongse; Paul Scott Thorner
Journal:  J Am Soc Nephrol       Date:  2010-06-17       Impact factor: 10.121

3.  Intramyocardial VEGF-B167 gene delivery delays the progression towards congestive failure in dogs with pacing-induced dilated cardiomyopathy.

Authors:  Martino Pepe; Mohammed Mamdani; Lorena Zentilin; Anna Csiszar; Khaled Qanud; Serena Zacchigna; Zoltan Ungvari; Uday Puligadda; Silvia Moimas; Xiaobin Xu; John G Edwards; Thomas H Hintze; Mauro Giacca; Fabio A Recchia
Journal:  Circ Res       Date:  2010-04-29       Impact factor: 17.367

4.  Ex vivo activation of angiogenic property in human peripheral blood-derived monocytes by thrombopoietin.

Authors:  Toru Kawamoto; Junpei Sasajima; Yoshiaki Sugiyama; Kazumasa Nakamura; Hiroki Tanabe; Mikihiro Fujiya; Toshie Nata; Yasuyuki Iuchi; Toshifumi Ashida; Yoshihiro Torimoto; Yusuke Mizukami; Yutaka Kohgo
Journal:  Int J Hematol       Date:  2013-09-04       Impact factor: 2.490

5.  Tissue type plasminogen activator regulates myeloid-cell dependent neoangiogenesis during tissue regeneration.

Authors:  Makiko Ohki; Yuichi Ohki; Makoto Ishihara; Chiemi Nishida; Yoshihiko Tashiro; Haruyo Akiyama; Hiromitsu Komiyama; Leif R Lund; Atsumi Nitta; Kiyofumi Yamada; Zhenping Zhu; Hideoki Ogawa; Hideo Yagita; Ko Okumura; Hiromitsu Nakauchi; Zena Werb; Beate Heissig; Koichi Hattori
Journal:  Blood       Date:  2010-01-28       Impact factor: 22.113

Review 6.  The role of the semaphorins in cancer.

Authors:  Gera Neufeld; Yelena Mumblat; Tatyana Smolkin; Shira Toledano; Inbal Nir-Zvi; Keren Ziv; Ofra Kessler
Journal:  Cell Adh Migr       Date:  2016-08-17       Impact factor: 3.405

7.  Allergen-induced, eotaxin-rich, proangiogenic bone marrow progenitors: a blood-borne cellular envoy for lung eosinophilia.

Authors:  Kewal Asosingh; Jodi D Hanson; Georgiana Cheng; Mark A Aronica; Serpil C Erzurum
Journal:  J Allergy Clin Immunol       Date:  2010-03-15       Impact factor: 10.793

8.  Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells.

Authors:  Boaz Kigel; Asya Varshavsky; Ofra Kessler; Gera Neufeld
Journal:  PLoS One       Date:  2008-09-26       Impact factor: 3.240

Review 9.  The role of semaphorins and their receptors in vascular development and cancer.

Authors:  Chenghua Gu; Enrico Giraudo
Journal:  Exp Cell Res       Date:  2013-02-17       Impact factor: 3.905

10.  Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle.

Authors:  Andrey Anisimov; Annamari Alitalo; Petra Korpisalo; Jarkko Soronen; Seppo Kaijalainen; Veli-Matti Leppänen; Michael Jeltsch; Seppo Ylä-Herttuala; Kari Alitalo
Journal:  Circ Res       Date:  2009-05-14       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.